Author

Julia Ford

SAFETY, PHARMACOKINETIC, BIOMARKER, HISTOLOGIC, AND RECTAL BLEEDING ACTIVITY FOLLOWING TREATMENT WITH THE GUT-TARGETED, PHD-INHIBITOR AND HIF-1? STABILIZER GB004 IN A PHASE 1B TRIAL IN MILD-TO-MODERATE ULCERATIVE COLITIS
SAFETY, PHARMACOKINETIC, BIOMARKER, HISTOLOGIC, AND RECTAL BLEEDING ACTIVITY FOLLOWING TREATMENT WITH THE GUT-TARGETED, PHD-INHIBITOR AND HIF-1? STABILIZER GB004 IN A PHASE 1B TRIAL IN MILD-TO-MODERATE ULCERATIVE COLITIS

Julia Ford  et al.

Item 1 - 1 / 1
1